Stock Track | Avanos Medical Soars 10.09% Pre-Market on Q3 Earnings Beat and Raised Full-Year Guidance

Stock Track11-05

Shares of Avanos Medical (NYSE: AVNS) surged 10.09% in pre-market trading on Wednesday following the company's impressive third-quarter earnings report that significantly surpassed analyst expectations. The medical technology company also raised its full-year guidance, further boosting investor confidence.

For the third quarter of 2025, Avanos Medical reported adjusted earnings per share of $0.22, substantially beating the analyst consensus estimate of $0.12. The company's quarterly sales reached $177.8 million, surpassing the expected $164.5 million and representing a 4.3% increase compared to the same period last year. The strong performance was primarily driven by double-digit growth in the Specialty Nutrition Solutions (SNS) segment, which saw increased demand for enteral feeding and neonate solutions.

In light of the robust results, Avanos Medical raised its full-year 2025 guidance. The company now expects annual revenue to be between $690 million and $700 million, with adjusted earnings per share projected in the range of $0.85 to $0.95. The improved outlook reflects the company's confidence in its growth strategy and market position, despite noting some uncertainty related to tariffs affecting the financial outlook. Additionally, the positive impact of the Nexus Medical acquisition is expected to benefit neonatal and pediatric intensive care units, further contributing to the company's optimistic prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142655686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142655686","market":"sg","top_or_hot":-1,"title":"Stock Track | Avanos Medical Soars 10.09% Pre-Market on Q3 Earnings Beat and Raised Full-Year Guidance","media":"Stock Track","content":"<p>Shares of Avanos Medical (NYSE: AVNS) surged 10.09% in pre-market trading on Wednesday following the company's impressive third-quarter earnings report that significantly surpassed analyst expectations. The medical technology company also raised its full-year guidance, further boosting investor confidence.</p>\n\n<p>For the third quarter of 2025, Avanos Medical reported adjusted earnings per share of $0.22, substantially beating the analyst consensus estimate of $0.12. The company's quarterly sales reached $177.8 million, surpassing the expected $164.5 million and representing a 4.3% increase compared to the same period last year. The strong performance was primarily driven by double-digit growth in the Specialty Nutrition Solutions (SNS) segment, which saw increased demand for enteral feeding and neonate solutions.</p>\n\n<p>In light of the robust results, Avanos Medical raised its full-year 2025 guidance. The company now expects annual revenue to be between $690 million and $700 million, with adjusted earnings per share projected in the range of $0.85 to $0.95. The improved outlook reflects the company's confidence in its growth strategy and market position, despite noting some uncertainty related to tariffs affecting the financial outlook. Additionally, the positive impact of the Nexus Medical acquisition is expected to benefit neonatal and pediatric intensive care units, further contributing to the company's optimistic prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avanos Medical Soars 10.09% Pre-Market on Q3 Earnings Beat and Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avanos Medical Soars 10.09% Pre-Market on Q3 Earnings Beat and Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Avanos Medical (NYSE: AVNS) surged 10.09% in pre-market trading on Wednesday following the company's impressive third-quarter earnings report that significantly surpassed analyst expectations. The medical technology company also raised its full-year guidance, further boosting investor confidence.</p>\n\n<p>For the third quarter of 2025, Avanos Medical reported adjusted earnings per share of $0.22, substantially beating the analyst consensus estimate of $0.12. The company's quarterly sales reached $177.8 million, surpassing the expected $164.5 million and representing a 4.3% increase compared to the same period last year. The strong performance was primarily driven by double-digit growth in the Specialty Nutrition Solutions (SNS) segment, which saw increased demand for enteral feeding and neonate solutions.</p>\n\n<p>In light of the robust results, Avanos Medical raised its full-year 2025 guidance. The company now expects annual revenue to be between $690 million and $700 million, with adjusted earnings per share projected in the range of $0.85 to $0.95. The improved outlook reflects the company's confidence in its growth strategy and market position, despite noting some uncertainty related to tariffs affecting the financial outlook. Additionally, the positive impact of the Nexus Medical acquisition is expected to benefit neonatal and pediatric intensive care units, further contributing to the company's optimistic prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVNS","symbol_name":"AVANOS MEDICAL","start_time":0,"source_url":"","article_id":"1142655686","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142655686","pubTimestamp":1762353356,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Avanos Medical (NYSE: AVNS) surged 10.09% in pre-market trading on Wednesday following the company's impressive third-quarter earnings report that significantly surpassed analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVNS":"AVANOS MEDICAL"},"translate_title":"个股追踪|Avanos Medical盘前飙升10.09%，因Q3盈利超预期并上调全年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVNS":1},"content_text":"Shares of Avanos Medical (NYSE: AVNS) surged 10.09% in pre-market trading on Wednesday following the company's impressive third-quarter earnings report that significantly surpassed analyst expectations. The medical technology company also raised its full-year guidance, further boosting investor confidence.\nFor the third quarter of 2025, Avanos Medical reported adjusted earnings per share of $0.22, substantially beating the analyst consensus estimate of $0.12. The company's quarterly sales reached $177.8 million, surpassing the expected $164.5 million and representing a 4.3% increase compared to the same period last year. The strong performance was primarily driven by double-digit growth in the Specialty Nutrition Solutions (SNS) segment, which saw increased demand for enteral feeding and neonate solutions.\nIn light of the robust results, Avanos Medical raised its full-year 2025 guidance. The company now expects annual revenue to be between $690 million and $700 million, with adjusted earnings per share projected in the range of $0.85 to $0.95. The improved outlook reflects the company's confidence in its growth strategy and market position, despite noting some uncertainty related to tariffs affecting the financial outlook. Additionally, the positive impact of the Nexus Medical acquisition is expected to benefit neonatal and pediatric intensive care units, further contributing to the company's optimistic prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142655686","isCrawlerRequest":true}